Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer.

Lambracht-Washington D, Fu M, Frost P, Rosenberg RN.

Alzheimers Res Ther. 2017 Apr 26;9(1):30. doi: 10.1186/s13195-017-0257-7.

2.

Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer.

Lambracht-Washington D, Fu M, Wight-Carter M, Riegel M, Rosenberg RN.

J Alzheimers Dis. 2017;57(1):97-112. doi: 10.3233/JAD-160947.

3.

A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients.

Lambracht-Washington D, Rosenberg RN.

Neurobiol Aging. 2015 Mar;36(3):1274-81. doi: 10.1016/j.neurobiolaging.2014.12.011. Epub 2014 Dec 12.

4.

Co-stimulation with TNF receptor superfamily 4/25 antibodies enhances in-vivo expansion of CD4+CD25+Foxp3+ T cells (Tregs) in a mouse study for active DNA Aβ42 immunotherapy.

Lambracht-Washington D, Rosenberg RN.

J Neuroimmunol. 2015 Jan 15;278:90-9. doi: 10.1016/j.jneuroim.2014.12.007. Epub 2014 Dec 10.

5.

Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease.

Lambracht-Washington D, Rosenberg RN.

Immunotargets Ther. 2013 Aug 1;2013(2):105-114.

6.

The neuroprotective effect of immune serum of adeno-associated virus vaccine containing Aβ1-15 gene on amyloid toxicity.

Liu LY, Ma YY, Yang T, Li X, Li W.

Ann Indian Acad Neurol. 2013 Oct;16(4):603-8. doi: 10.4103/0972-2327.120489.

7.

Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease.

Lambracht-Washington D, Rosenberg RN.

Transl Neurosci. 2012 Dec 1;3(4):307-313.

8.

Advances in the development of vaccines for Alzheimer's disease.

Lambracht-Washington D, Rosenberg RN.

Discov Med. 2013 May;15(84):319-26.

9.

DNA Aβ42 vaccination as possible alternative immunotherapy for Alzheimer disease.

Rosenberg RN, Lambracht-Washington D.

JAMA Neurol. 2013 Jun;70(6):772-3. doi: 10.1001/jamaneurol.2013.1502. Review. No abstract available.

10.

Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease.

Leclerc B, Abulrob A.

ScientificWorldJournal. 2013;2013:589308. doi: 10.1155/2013/589308. Epub 2013 Feb 5. Review.

11.

Current and future treatments for Alzheimer's disease.

Yiannopoulou KG, Papageorgiou SG.

Ther Adv Neurol Disord. 2013 Jan;6(1):19-33. doi: 10.1177/1756285612461679.

12.

A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.

Lambracht-Washington D, Qu BX, Fu M, Anderson LD Jr, Eagar TN, Stüve O, Rosenberg RN.

J Neuroimmunol. 2013 Jan 15;254(1-2):63-8. doi: 10.1016/j.jneuroim.2012.09.008. Epub 2012 Oct 1.

13.

DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.

Lambracht-Washington D, Qu BX, Fu M, Anderson LD Jr, Stüve O, Eagar TN, Rosenberg RN.

Cell Mol Neurobiol. 2011 Aug;31(6):867-74. doi: 10.1007/s10571-011-9680-7. Epub 2011 Apr 6.

Supplemental Content

Support Center